RxDoctor Payments Data

Bo Allaire, MD

Addiction Medicine · Bellaire, TXNPI 1235363862

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.

$5,624in general payments, 2019–2025

Across 320 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Indivior Inc.$740
  • Takeda Pharmaceuticals U.S.A., Inc.$610
  • Alkermes, Inc.$434
  • Eisai Inc.$291
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,58499%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,624 in reported general payments places this provider in the 85th percentile of 42 addiction medicine providers in Texas.

See all addiction medicine providers in Texas

Medicare billing

Part B allowed, 2024
$9,423
Medicare patients
48
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide13$7,132
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$3,497
Gabapentin48$746
Buspirone Hcl30$429
Bupropion XlBupropion Hcl12$349
Buprenorphine Hcl11$330
Sertraline Hcl14$330
Pregabalin18$310
Atorvastatin Calcium16$257
Trazodone Hcl47$254
Escitalopram Oxalate17$241
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine22$224
Methocarbamol12$188
Alprazolam40$138
Vitamin D2Ergocalciferol (Vitamin D2)16$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$610$7,13213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 addiction medicine providers in Texas.

Other addiction medicine in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →